Navigation Links
Professor collaborates on most comprehensive analyses of NSAIDs and coxibs

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of the Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs (NSAIDs), which include cyclo-oxygenase-2 inhibitors (coxibs).

Hennekens and colleagues from around the world, under the direction of the Clinical Trial Service and Epidemiology Studies Unit at the University of Oxford, conducted a world-wide meta-analyses using individual participant data from 280 trials of NSAIDs vs. placebo and 474 trials of NSAID vs. another NSAID, which involved a total of 353,809 participants and a total of 233,798 person-years. These results address risks and benefits of drugs used for relief of inflammatory arthritis including cardiovascular disease and other relevant outcomes such as gastrointestinal effects.

"The vascular risks of high-dose diclofenac and ibuprofen are comparable to coxibs, while high-dose naproxen is associated with less vascular risk than other NSAIDs," said Hennekens. "Although NSAIDs increase vascular and gastrointestinal risks, their magnitude can be predicted, which may help guide clinical decision-making."

David J. Bjorkman, MD, MSPH, dean of the Charles E. Schmidt College of Medicine at FAU and a gastroenterologist noted that "these are the most comprehensive analyses ever conducted of the benefits and risks of NSAIDs, which include coxibs, and should help guide healthcare providers in their prescribing patterns."

Hennekens concluded that "from a clinical and policy perspective, the available data suggest that for relief of pain of inflammatory arthritis, naproxen may have the best benefit-to-risk ratio on cardiovascular disease (CVD). In contrast to naproxen, other traditional NSAIDS and coxibs confer similar moderately increased risks of CVD. At present, individual clinical judgments about coxibs and nonselective NSAIDs should not be limited to risks of CVD. They should also include concerns about non-CVD risks, such as gastrointestinal bleeding and other benefits, including improved quality of life resulting from decreases in impairment from musculoskeletal pain syndromes."

Science Watch ranked Hennekens as the third most widely cited medical researcher in the world from 1995-2005, and five of the top 20 were his former trainees and/or fellows. In addition, in 2012 Science Heroes, ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives.


Contact: Gisele Galoustian
Florida Atlantic University

Related medicine news :

1. Louisiana Tech University professor earns NSF Early Career Development grant
2. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
3. Louisiana Tech biomedical engineering professor earns recognition, funding for research
4. Women professorships low in some Scandinavian universities due to sexism
5. President Obama names SF State math professor a top young scientist
6. From textbook to flexbook: Professor uses new collaborative tool in the classroom
7. IHME professor named first health measurement winner of prestigious innovation award
8. Guys, take note: Male birth control pill may be ready soon, says Texas A&M professor
9. UBC professor wins Canadas top pharmaceutical research award
10. Huddersfield professors ground-breaking research shows just how well the 2012 Games were run
11. Grove Professor receives $1.5MM to study breast cancer therapies
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: